BioCentury | Nov 6, 2019
Company News

Biogen expanding biosimilars deal for eye therapies, anti-TNFs

As it continues to rely on biosimilars as a growth driver, Biogen has expanded its deal with Samsung Bioepis to include two new ocular biosimilars in certain major markets, as well as rights in China...
BioCentury | Nov 7, 2018
Emerging Company Profile

ABL bispecifics

Korean biotech ABL Bio Inc. is developing bispecifics for cancer and Parkinson’s disease, and has evidence suggesting its lead candidate against VEGF and DLL4 is more potent than at least one of its Western competitors....
BioCentury | Apr 19, 2018
Translation in Brief

One-two punch for West Nile

In a one-two punch, a group from Yale University and Hanyang University developed an intranasal therapy that treated West Nile viral infection and prevented its recurrence by promoting natural immunity in mice, effectively creating a...
BioCentury | Apr 17, 2018
Distillery Therapeutics

Infectious disease

INDICATION: West Nile virus Mouse studies suggest intranasal delivery of siRNA targeting West Nile virus protein E could help treat and prevent the recurrence of West Nile viral infection. In mice with neuroinvasive West Nile...
BioCentury | Jan 31, 2018
Distillery Therapeutics

Cancer

INDICATION: Brain cancer; breast cancer; colorectal cancer Cell culture and mouse studies identified an indole-quinoline-based dual PIP4K2A/PIP4K2C inhibitor that could help treat Ras-driven glioma, breast cancer and colorectal cancer. Screening of a small molecule library...
BioCentury | Jan 17, 2018
Distillery Therapeutics

Neurology

INDICATION: Parkinson’s disease (PD) In vitro and rat studies suggest co-transplantation of neural progenitor cells (NPCs) and astrocytes expressing NURR1 and FOXA2 could help treat PD. In mouse or rat ventral midbrain-derived NPCs, co-culture with...
BioCentury | Dec 10, 2016
Finance

SillaJen slides onto KOSDAQ

A combination of a large number of private shareholders and unlucky timing soured the KOSDAQ debut of SillaJen Inc. (KOSDAQ:215600), but the proceeds should finance the cancer immunotherapy company’s Phase III trial for oncolytic virus...
BioCentury | Nov 21, 2016
Strategy

LG’s biotech legacy

LG Life Sciences Ltd. was a pioneer, producing the first globally approved drugs developed by a South Korean company. A shift in priorities all but stopped the flow of innovative new drugs to the world...
BioCentury | Aug 11, 2016
Distillery Therapeutics

Therapeutics: Wnt pathway

Ophthalmic disease INDICATION: Ophthalmic disease Mouse studies suggest Wnt pathway-activated hematopoietic stem and progenitor cells (HSPCs) could help treat retinitis pigmentosa and other forms of retinal degeneration. In a mouse model of chemical-induced photoreceptor degeneration,...
BioCentury | May 26, 2016
Distillery Therapeutics

Therapeutics: E. Coli extra catalase gene

Infectious disease INDICATION: Cholera Cell culture and mouse studies suggest inhibiting E. coli eKatE could help treat cholera. In mice challenged with Vibrio cholerae, pretreatment with low doses of the generic antibiotics streptomycin or vancomycin...
Items per page:
1 - 10 of 354
BioCentury | Nov 6, 2019
Company News

Biogen expanding biosimilars deal for eye therapies, anti-TNFs

As it continues to rely on biosimilars as a growth driver, Biogen has expanded its deal with Samsung Bioepis to include two new ocular biosimilars in certain major markets, as well as rights in China...
BioCentury | Nov 7, 2018
Emerging Company Profile

ABL bispecifics

Korean biotech ABL Bio Inc. is developing bispecifics for cancer and Parkinson’s disease, and has evidence suggesting its lead candidate against VEGF and DLL4 is more potent than at least one of its Western competitors....
BioCentury | Apr 19, 2018
Translation in Brief

One-two punch for West Nile

In a one-two punch, a group from Yale University and Hanyang University developed an intranasal therapy that treated West Nile viral infection and prevented its recurrence by promoting natural immunity in mice, effectively creating a...
BioCentury | Apr 17, 2018
Distillery Therapeutics

Infectious disease

INDICATION: West Nile virus Mouse studies suggest intranasal delivery of siRNA targeting West Nile virus protein E could help treat and prevent the recurrence of West Nile viral infection. In mice with neuroinvasive West Nile...
BioCentury | Jan 31, 2018
Distillery Therapeutics

Cancer

INDICATION: Brain cancer; breast cancer; colorectal cancer Cell culture and mouse studies identified an indole-quinoline-based dual PIP4K2A/PIP4K2C inhibitor that could help treat Ras-driven glioma, breast cancer and colorectal cancer. Screening of a small molecule library...
BioCentury | Jan 17, 2018
Distillery Therapeutics

Neurology

INDICATION: Parkinson’s disease (PD) In vitro and rat studies suggest co-transplantation of neural progenitor cells (NPCs) and astrocytes expressing NURR1 and FOXA2 could help treat PD. In mouse or rat ventral midbrain-derived NPCs, co-culture with...
BioCentury | Dec 10, 2016
Finance

SillaJen slides onto KOSDAQ

A combination of a large number of private shareholders and unlucky timing soured the KOSDAQ debut of SillaJen Inc. (KOSDAQ:215600), but the proceeds should finance the cancer immunotherapy company’s Phase III trial for oncolytic virus...
BioCentury | Nov 21, 2016
Strategy

LG’s biotech legacy

LG Life Sciences Ltd. was a pioneer, producing the first globally approved drugs developed by a South Korean company. A shift in priorities all but stopped the flow of innovative new drugs to the world...
BioCentury | Aug 11, 2016
Distillery Therapeutics

Therapeutics: Wnt pathway

Ophthalmic disease INDICATION: Ophthalmic disease Mouse studies suggest Wnt pathway-activated hematopoietic stem and progenitor cells (HSPCs) could help treat retinitis pigmentosa and other forms of retinal degeneration. In a mouse model of chemical-induced photoreceptor degeneration,...
BioCentury | May 26, 2016
Distillery Therapeutics

Therapeutics: E. Coli extra catalase gene

Infectious disease INDICATION: Cholera Cell culture and mouse studies suggest inhibiting E. coli eKatE could help treat cholera. In mice challenged with Vibrio cholerae, pretreatment with low doses of the generic antibiotics streptomycin or vancomycin...
Items per page:
1 - 10 of 354